DOCSLIB.ORG

A Review of Anticoagulant Rodenticides in Current Use

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
A Review of Anticoagulant Rodenticides in Current Use Bull. Org. mond. SantJ 1972, 47, 275-280 Bull. Wid Hith Org. A review of anticoagulant rodenticides in current use E. W. BENTLEY 1 The advent of anticoagulant rodenticides in the some are discernibly better than others for the control early 1950s undoubtedly marked a turning point in of certain species of rodent. In some instances this rodent control. These substances have two main can be ascribed to an obvious physiological effect. It advantages in comparison with the acute poisons. is well known, for example, that at the recommended First, when used in appropriate concentrations, dosages some anticoagulants affect the clotting fac- anticoagulants do not produce symptoms in the tors in mammalian blood much more quickly than rodent that cause it to stop feeding before a lethal others. Similarly, the effect of one anticoagulant on dose has been ingested. This characteristic makes the clotting factors may fall off more quickly than the complete eradication of discrete infestations that of another. In some instances, variations in the possible, provided that baiting is efficient and con- effectiveness of different anticoagulants in the field tinued over a long enough period. Second, birds are may reflect differences in palatability, which may de- relatively resistant to anticoagulants, and although pend partly on the concentration of the poison. all mammals are affected they generally acquire a In view of these differences in effectiveness, it is of lethal dose only after feeding on the bait on more interest to note that anticoagulant usage varies wide- than one occasion; moreover, vitamin K1 is a power- ly from one country to another. The literature on ful antidote if it is administered in time. Thus acci- rodent control published during the last few years dental deaths involving anticoagulants are easier to shows that, in addition to warfarin (with or with- prevent. Their main disadvantage is that bait must out the addition of N14-pyrimidinyl sulfanilamide usually be laid down more often than in treatments (" sulfaquinoxaline "), the following rodenticides with acute poisons, but this is only apparent if the are favoured: latter are conducted without pre-baiting, in which Country Anticoagulant case there would be an accompanying loss of effec- Canada coumachlor, pindone tiveness. Federal Republic coumachlor, coumafuryl, All the anticoagulant rodenticides on the market of Germany coumatetralyl at the present time are either coumarin derivatives Finland dicoumarol or indandiones. Except in a few small areas of the France chlorophacinone, coumachlor, world where " resistance " has appeared, these sub- 2-[1-(p-bromophenyl)-1-phenyl]- stances control at least the common rat, Rattus nor- acetyl-1,3-indandione vegicus, reasonably well. The best anticoagulants India coumatetralyl can be very effective indeed, although different Israel pindone sodium in different countries. For example, Malaysia coumachlor claims are made Mexico coumafuryl warfarin is expected to give 100 % control of R. nor- Philippines pindone vegicus infestations in built-up areas in some coun- Poland diphacinone tries, but in others an 85 % or higher rate of control United Kingdom coumatetralyl, chlorophacinone is considered to be " successful ". Such differences USA coumafuryl, diphacinone, pindone, may depend on the techniques used in control pro- 2-isovaleryl-1,3-indandione grammes, but basically they are almost certainly USSR chlorophacinone, diphacinone, related to the amount of control effort that it is con- 2-[1-(p-tolyl)-l-phenyl]acetyl-1,3- sidered economical to expend in different situations. indandione Although most of the anticoagulants on sale are These variations are undoubtedly due largely to generally effective, laboratory tests have shown that commercial and financial considerations and to patent laws. In some countries, for example, war- 1 Ministry of Agriculture, Fisheries, and Food, Tolworth, England. farin has become so well established that it would 2896 -275- 276 E. W. BENTLEY be difficult and commercially hazardous to market diphacinone was approximately as toxic and accept- another product. However, two other factors may able to M. musculus as 0.025% warfarin, and that also be involved-namely, the need for more com- 0.005 % chlorophacinone and 0.025 % pindone were parative studies on the effectiveness of the various rather more toxic than either of those substances. substances and for the better interchange of labora- However, pindone was somewhat less acceptable to tory and field results among control biologists work- mice than the other substances. Rowe & Redfern ing in different countries. (1968b) also concluded that 0.05 % coumatetralyl was Most of the published work on the comparative as acceptable and toxic to house mice as 0.025% evaluation of anticoagulants for use against com- warfarin; although coumatetralyl was more toxic mensal rodents has been carried out in government than warfarin against individual animals particularly laboratories. In the United Kingdom all but one of resistant to anticoagulants, both substances had the substances listed above have been examined for shortcomings in this respect. their effectiveness against R. norvegicus and Mus The most informative publication from the USA on musculus, and, to a lesser extent, R. rattus. As far the comparative efficacy ofanticoagulantrodenticides as R. norvegicus is concerned, Bentley & Rowe is that of Hayes & Gaines (1959), who endeavoured (1956) and Bentley & Larthe (1959) came to the to assess the probable field effectiveness of warfarin, conclusion, based on separate toxicity and palat- coumachlor, pindone, diphacinone, and the calcium ability tests, that warfarin and coumafuryl used at salt of2-isovaleryl-1,3-indandione by laboratory toxi- a concentration of 0.005% or 0.025% would pro- city tests in which plain bait was also available to the duce the best results in the field, and that couma- test animals. Their main conclusion was that " the chlor, pindone, chlorophacinone, 2-(1-naphthyl)-1,3- performance of warfarin against the commensal ro- indandione, or 2-isovaleryl-1,3-indandione would dents was not excelled by the other anticoagulant not give quite such good results at any concentration. compounds tested. Diphacinone was about as good Greaves & Ayres (1969) later compared warfarin as warfarin against wild Norway rats. [Pindone] was with coumatetralyl and found that the latter used at about equal to warfarin against roof rats (Rattus concentrations of 0.05% and 0.005% was about rattus) and mice, but, like coumachlor, was some- as toxic as warfarin used at a concentration of what inferior against wild Norway rats ". The cal- 0.005%, and was at least as palatable. Their view cium salt of2-isovaleryl-1,3-indandione was consider- that coumatetralyl would prove to be a good sub- ed to be inferior to the other poisons against all three stitute for warfarin has been borne out by subsequent species of rodent. Later, these findings seem to have field experience in the United Kingdom. been incorporated in an official recommendation (US The most effective poison against R. rattus was Public Health Service, 1962) to use diphacinone, found by Bentley & Larthe (1959) to be diphacinone coumafuryl, pindone, or warfarin against any of the at a concentration of 0.0125 %. Warfarin and couma- three commensal species at the dosage rates given in furyl, both used at a concentration of 0.025 %, were Table 1. less effective. Insufficient studies have been made to More recently, Merrill (1969) reported that these rank the effectiveness of coumachlor, 2-(1-naphthyl)- four anticoagulants and the calcium salt of 2-iso- 1,3-indandione, 2-isovaleryl-1 ,3-indandione, and valeryl-1,3-indandione were being used against R. chlorophacinone against R. rattus. norvegicus at concentrations in bait of 0.025 % for Rowe & Redfern (1968a) reported that 0.0125% warfarin, coumafuryl, and pindone, 0.05 % for the Table 1. Dosage levels recommended by the US Public Health Service (1962) for anticoagulant rodenticides Anticoagulant M. musculus R. rattus R. norvegicus diphacinone 0.0125-0.025 % 0.005-0.01 % 0.005-0.01 % coumafuryl, pindone 0.025 -0.5 % 0.025 % 0.025 % warfarin 0.025 -0.05 % 0.025 % 0.005-0.025 % CURRENT ANTICOAGULANT RODENTICIDES 277 calcium salt, and 0.005% for diphacinone. It will about 10 tonnes per annum were being produced be seen that it is not now recommended to use by 1965. Compound (3) was said to be highly toxic warfarin at a concentration of 0.005%. In the not only to R. norvegicus but also to M. musculus and United Kingdom also, the recommended concentra- the susliks, Citellus citellus and C. suslicus. In 1968 tion is now 0.025 %, the reason being that it is opera- the All-Union Plant Protection Research Institute tionally more convenient to have a single concentra- of the USSR reported that compound (3) was widely tion for use against all three commensal species of used for controlling rats and mice, and that chloro- rodent, and that 0.025 % may, in some circum- phacinone was undergoing further field trials. stances, lead to more rapid mortality and a corre- In addition to the work described above, Telle spondingly shorter treatment. These advantages have (1963) investigated the palatability to R. norvegicus of course, to be balanced against the higher risk to and R. rattus of warfarin, coumachlor, couma- livestock and pets. tetralyl, and " pyranocoumarin". The two latter com- It will be seen that there is very little disagreement pounds were apparently undetectable at the concen- between workers in the United Kingdom and the trations studied. Both coumachlor and warfarin re- USA. Such differences as do occur may be explained veal some degree of unacceptability at about the in terms of differences between the rodents them- 0.05 % level; this finding agrees with results reported selves; certainly this could be so for M. musculus. elsewhere (e.g., Bentley & Larthe, 1959). In the USSR most attention has been paid to the A few other anticoagulant compounds have been indandiones.
Load more

Recommended publications
  • Enoxaparin Sodium Solution for Injection, Manufacturer's Standard
    PRODUCT MONOGRAPH INCLUDING PATIENT MEDICATION INFORMATION PrLOVENOX® Enoxaparin sodium solution for injection 30 mg in 0.3 mL solution (100 mg/mL), pre-filled syringes for subcutaneous or intravenous injection 40 mg in 0.4 mL solution (100 mg/mL), pre-filled syringes for subcutaneous or intravenous injection 60 mg in 0.6 mL solution (100 mg/mL), pre-filled syringes for subcutaneous or intravenous injection 80 mg in 0.8 mL solution (100 mg/mL), pre-filled syringes for subcutaneous or intravenous injection 100 mg in 1 mL solution (100 mg/mL), pre-filled syringes for subcutaneous or intravenous injection 300 mg in 3 mL solution (100 mg/mL), multidose vials for subcutaneous or intravenous injection PrLOVENOX® HP Enoxaparin sodium (High Potency) solution for injection 120 mg in 0.8 mL solution (150 mg/mL), pre-filled syringes for subcutaneous or intravenous injection 150 mg in 1 mL solution (150 mg/mL), pre-filled syringes for subcutaneous or intravenous injection Manufacturer’s standard Anticoagulant/Antithrombotic Agent ATC Code: B01AB05 Product Monograph – LOVENOX (enoxaparin) Page 1 of 113 sanofi-aventis Canada Inc. Date of Initial Approval: 2905 Place Louis-R.-Renaud February 9, 1993 Laval, Quebec H7V 0A3 Date of Revision September 7, 2021 Submission Control Number: 252514 s-a version 15.0 dated September 7, 2021 Product Monograph – LOVENOX (enoxaparin) Page 2 of 113 TABLE OF CONTENTS Sections or subsections that are not applicable at the time of authorization are not listed. TABLE OF CONTENTS ..............................................................................................................
    [Show full text]
  • Rivaroxaban Versus Warfarin for Treatment and Prevention Of
    Costa et al. Thrombosis Journal (2020) 18:6 https://doi.org/10.1186/s12959-020-00219-w RESEARCH Open Access Rivaroxaban versus warfarin for treatment and prevention of recurrence of venous thromboembolism in African American patients: a retrospective cohort analysis Olivia S. Costa1,2, Stanley Thompson3, Veronica Ashton4, Michael Palladino5, Thomas J. Bunz6 and Craig I. Coleman1,2* Abstract Background: African Americans are under-represented in trials evaluating oral anticoagulants for the treatment of acute venous thromboembolism (VTE). The aim of this study was to evaluate the effectiveness and safety of rivaroxaban versus warfarin for the treatment of VTE in African Americans. Methods: We utilized Optum® De-Identified Electronic Health Record data from 11/1/2012–9/30/2018. We included African Americans experiencing an acute VTE during a hospital or emergency department visit, who received rivaroxaban or warfarin as their first oral anticoagulant within 7-days of the acute VTE event and had ≥1 provider visit in the prior 12-months. Differences in baseline characteristics between cohorts were adjusted using inverse probability-of-treatment weighting based on propensity scores (standard differences < 0.10 were achieved for all covariates). Our primary endpoint was the composite of recurrent VTE or major bleeding at 6-months. Three- and 12-month timepoints were also assessed. Secondary endpoints included recurrent VTE and major bleeding as individual endpoints. Cohort risk was compared using Cox regression and reported as hazard ratios (HRs) with 95% confidence intervals (CIs). Results: We identified 2097 rivaroxaban and 2842 warfarin users with incident VTE. At 6-months, no significant differences in the composite endpoint (HR = 0.96, 95%CI = 0.75–1.24), recurrent VTE (HR = 1.02, 95%CI = 0.76–1.36) or major bleeding alone (HR = 0.93, 95%CI = 0.59–1.47) were observed between cohorts.
    [Show full text]
  • Occurrence, Elimination, and Risk of Anticoagulant Rodenticides in Wastewater and Sludge
    Occurrence, elimination, and risk of anticoagulant rodenticides in wastewater and sludge Silvia Lacorte, Cristian Gómez- Canela Department of Environmental Chemistry, IDAEA-CSIC, Jordi Girona 18-26, 08034 Barcelona Rats and super-rats Neverending story 1967 Coumachlor 1 tn rodenticides /city per campaign “It will be the LAST ONE” Rodenticides Biocides: use regulated according to EU. Used mainly as bait formulations. First generation: multiple feedings, less persistent in tissues, commensal and outdoor use. Second generation: single feeding (more toxic), more persistent in tissue, commensal use only. Toxic: vitamin K antagonists that cause mortality by blocking an animal’s ability to produce several key blood clotting factors. High oral, dermal and inhalation toxicity. Origin and fate of rodenticides Study site: Catalonia (7.5 M inhabitants) 1693 km of sewage corridor 13 fluvial tanks (70.000 m3) 130,000,000 € / 8 YEARS 32,000 km2 378,742 kg/y AI 2,077,000 € Objectives 1. To develop an analytical method to determine most widely used rodenticides in wastewater and sludge. 2. To monitor the presence of rodenticides within 9 WWTP receiving urban and agricultural waters. 3. To evaluate the risk of rodenticides using Daphnia magna as aquatic toxicological model. 4. To study the accumulation of rodenticides in sludge. Compounds studied Coumachlor* Pindone C19H15ClO4 C14H14O3 Dicoumarol Warfarin C19H12O6 C19H16O4 Coumatetralyl Ferulenol FGARs C19H16O3 C24H30O3 Acenocoumarol Chlorophacinone • Solubility C19H15NO6 C23H15ClO3 0.001-128 mg/L • pKa 3.4-6.6 Flocoumafen Bromadiolone C H F O C H BrO 33 25 3 40 30 23 4 • Log P 1.92-8.5 Brodifacoum Fluindione C H BrO 31 23 3 C15H9FO2 SGARs Difenacoum Fenindione C31H24O3 C15H10O2 1.
    [Show full text]
  • Wastewater-Borne Exposure of Limnic Fish to Anticoagulant Rodenticides
    Water Research 167 (2019) 115090 Contents lists available at ScienceDirect Water Research journal homepage: www.elsevier.com/locate/watres Wastewater-borne exposure of limnic fish to anticoagulant rodenticides * Julia Regnery a, , Pia Parrhysius a, Robert S. Schulz a, Christel Mohlenkamp€ a, Georgia Buchmeier b, Georg Reifferscheid a, Marvin Brinke a a Department of Biochemistry, Ecotoxicology, Federal Institute of Hydrology, Am Mainzer Tor 1, 56068 Koblenz, Germany b Unit Aquatic Ecotoxicology, Microbial Ecology, Bavarian Environment Agency, Demollstr. 31, 82407 Wielenbach, Germany article info abstract Article history: The recent emergence of second-generation anticoagulant rodenticides (AR) in the aquatic environment Received 18 June 2019 emphasizes the relevance and impact of aquatic exposure pathways during rodent control. Pest control Received in revised form in municipal sewer systems of urban and suburban areas is thought to be an important emission 12 September 2019 pathway for AR to reach wastewater and municipal wastewater treatment plants (WWTP), respectively. Accepted 13 September 2019 To circumstantiate that AR will enter streams via effluent discharges and bioaccumulate in aquatic or- Available online 14 September 2019 ganisms despite very low predicted environmental emissions, we conducted a retrospective biological monitoring of fish tissue samples from different WWTP fish monitoring ponds exclusively fed by Keywords: fl Bioaccumulation municipal ef uents in Bavaria, Germany. At the same time, information about rodent control in asso- Biocides ciated sewer systems was collected by telephone survey to assess relationships between sewer baiting Monitoring and rodenticide residues in fish. In addition, mussel and fish tissue samples from several Bavarian surface PBT-Substances waters with different effluent impact were analyzed to evaluate the prevalence of anticoagulants in Sewer baiting indigenous aquatic organisms.
    [Show full text]
  • Design for the Environment Toolkit: a Competitive Edge for the Future
    Design for the Environment A Competitive Edge for the Future Toolkit Design for Environment Toolkit(DfE) Minnesota Office of Environmental Assistance Minnesota Technical Assistance Program (MnTAP) Table of Contents vAbout the Authors...2 vAcknowledgments...3 vPreface...4 vPart One: Introduction to Design for the Environment (DfE)...6 What is DfE?...6 Why DfE?...10 Success in DfE...12 Implementing DfE...13 vPart Two: DfE Matrices and Questions...17 Explanation of the DfE Matrix System..17 Figure: Product DfE Matrix...18 Instructions For Using the DfE Matrix...19 Interpretation of Results...28 Matrix Questions...20 Definitions...30 vPart Three: Reference Information...32 Index of Hazardous Chemical Pollutants (alphabetical listing)...32 Plastics Environmental Risk Information...57 Figure: Recycling Rates and Commodity Price Information....58 Index of Climate Altering Chemicals...59 Polymers....61 Degradable Polymers - Vendor List...62 Part/Materials Suppliers Environmental Survey...65 Additional Resources...66 Works Cited....68 Summary of References...69 Other Vendor Lists Checklist of Printed Resources for Minnesota Businesses Outlets for Industrial Scrap Pallets Alternative Solvent Degreasers Manufacturers of Aqueous Cleaning Equipment Aqueous and Semi-Aqueous Cleaners for Metal Part Degreasing Safer Stripping and Cleaning Chemicals for Coatings and Polymers Page 1 About the Authors Jeremy M. Yarwood - Research Specialist, Minnesota Technical Assistance Program (MnTAP) Mr. Yarwood has previously worked with MnTAP advising Minnesota companies in developing environmentally responsible processes. He received his B.S. Civil (Environmental) Engineering summa cum laude from the University of Minnesota. Mr. Yarwood is currently a graduate fellow in the Department of Civil Engineering at the University of Minnesota and plans to obtain a M.S.
    [Show full text]
  • Pharmacokinetics of Anticoagulant Rodenticides in Target and Non-Target Organisms Katherine Horak U.S
    University of Nebraska - Lincoln DigitalCommons@University of Nebraska - Lincoln USDA National Wildlife Research Center - Staff U.S. Department of Agriculture: Animal and Plant Publications Health Inspection Service 2018 Pharmacokinetics of Anticoagulant Rodenticides in Target and Non-target Organisms Katherine Horak U.S. Department of Agriculture, [email protected] Penny M. Fisher Landcare Research Brian M. Hopkins Landcare Research Follow this and additional works at: https://digitalcommons.unl.edu/icwdm_usdanwrc Part of the Life Sciences Commons Horak, Katherine; Fisher, Penny M.; and Hopkins, Brian M., "Pharmacokinetics of Anticoagulant Rodenticides in Target and Non- target Organisms" (2018). USDA National Wildlife Research Center - Staff Publications. 2091. https://digitalcommons.unl.edu/icwdm_usdanwrc/2091 This Article is brought to you for free and open access by the U.S. Department of Agriculture: Animal and Plant Health Inspection Service at DigitalCommons@University of Nebraska - Lincoln. It has been accepted for inclusion in USDA National Wildlife Research Center - Staff ubP lications by an authorized administrator of DigitalCommons@University of Nebraska - Lincoln. Chapter 4 Pharmacokinetics of Anticoagulant Rodenticides in Target and Non-target Organisms Katherine E. Horak, Penny M. Fisher, and Brian Hopkins 1 Introduction The concentration of a compound at the site of action is a determinant of its toxicity. This principle is affected by a variety of factors including the chemical properties of the compound (pKa, lipophilicity, molecular size), receptor binding affinity, route of exposure, and physiological properties of the organism. Many compounds have to undergo chemical changes, biotransformation, into more toxic or less toxic forms. Because of all of these variables, predicting toxic effects and performing risk assess- ments of compounds based solely on dose are less accurate than those that include data on absorption, distribution, metabolism (biotransformation), and excretion of the compound.
    [Show full text]
  • Some Rodenticidal Properties of Coumatetralyl
    J.Hyg.,Camb. (1969), 67, 311 311 Printed in Great Britain Some rodenticidal properties of coumatetralyl BY J. H. GREAVES AND PRISCILLA AYRES Infestation Control Laboratory, Ministry of Agriculture, Fisheries and Food, Tolworth, Surrey {Received 26 September 1968) INTRODUCTION Coumatetralyl (3-(a-tetralyl)-4-hydroxycoumarin), an anti-coagulant rodenti- cide developed by Farbenfabriken Bayer A.G., has been used extensively against rats in Germany (Schultze, 1965). Comparatively little information is available, however, concerning its rodenticidal properties. The present laboratory study was therefore undertaken to investigate the toxicity of the anti-coagulant to warfarin- resistant and warfarin-susceptible rats (Rattus norvegicus Berk.) and to compare its palatability with that of warfarin (3-(<x-acetonylbenzyl)-4-hydroxycoumarin). METHODS Wild rats, presumed not to be resistant to warfarin (NR rats) were caught in a Midlands refuse destructor and on a Surrey farm. Warfarin-resistant (WR) rats were trapped on farms in three different areas of Britain: Nottinghamshire (WR Notts), Gloucestershire (WR Glos) and the Salop-Montgomeryshire area (WR Welsh). Field investigations had shown that the rats on the Nottinghamshire and Gloucestershire farms could not be controlled with warfarin. All ten WR Glos rats used in tests with coumatetralyl had first been given, and had survived, un- restricted feeding for 6 days on 0-005 % warfarin in the laboratory and similarly all but six of the 23 WR Notts rats had first been given periods of from 3 to 6 days on warfarin. The 53 WR Welsh animals had survived either 6 days feeding on 0-005 % warfarin or a single subcutaneous injection of 200 mg./kg.
    [Show full text]
  • New Zealand Data Sheet 1
    New Zealand Data Sheet 1. PRODUCT NAME NAXEN® 250 mg tablets 2. QUALITATIVE AND QUANTITATIVE COMPOSITION Each NAXEN 250 mg tablet contains 250 mg of Naproxen For the full list of excipients, see section 6.1. 3. PHARMACEUTICAL FORM NAXEN 250 mg tablets are yellow, biconvex, round tablet of 11 mm diameter with one face engraved NX250 and having a bisecting score. The score line is only to facilitate breaking for ease of swallowing and not to divide into equal doses. 4. CLINICAL PARTICULARS 4.1. Therapeutic indications NAXEN is indicated in adults for the relief of symptoms associated with rheumatoid arthritis, osteoarthritis, ankylosing spondylitis, tendonitis and bursitis, acute gout and primary dysmenorrhoea. NAXEN is indicated in children for juvenile arthritis. 4.2. Dose and method of administration After assessing the risk/benefit ratio in each individual patient, the lowest effective dose for the shortest possible duration should be used (see Section 4.4). During long-term administration the dose of naproxen may be adjusted up or down depending on the clinical response of the patient. A lower daily dose may suffice for long-term administration. In patients who tolerate lower doses well, the dose may be increased to 1000 mg per day when a higher level of anti-inflammatory/analgesic 1 | P a g e activity is required. When treating patients with naproxen 1000 mg/day, the physician should observe sufficient increased clinical benefit to offset the potential increased risk. Dose Adults For rheumatoid arthritis, osteoarthritis and ankylosing spondylitis Initial therapy: The usual dose is 500-1000 mg per day taken in two doses at 12 hour intervals.
    [Show full text]
  • Heavy Rainfall Provokes Anticoagulant Rodenticides' Release from Baited
    Journal Pre-proof Heavy rainfall provokes anticoagulant rodenticides’ release from baited sewer systems and outdoor surfaces into receiving streams Julia Regnery1,*, Robert S. Schulz1, Pia Parrhysius1, Julia Bachtin1, Marvin Brinke1, Sabine Schäfer1, Georg Reifferscheid1, Anton Friesen2 1 Department of Biochemistry, Ecotoxicology, Federal Institute of Hydrology, 56068 Koblenz, Germany 2 Section IV 1.2 Biocides, German Environment Agency, 06813 Dessau-Rosslau, Germany *Corresponding author. Email: [email protected] (J. Regnery); phone: +49 261 1306 5987 Journal Pre-proof A manuscript prepared for possible publication in: Science of the Total Environment May 2020 1 Journal Pre-proof Abstract Prevalent findings of anticoagulant rodenticide (AR) residues in liver tissue of freshwater fish recently emphasized the existence of aquatic exposure pathways. Thus, a comprehensive wastewater treatment plant and surface water monitoring campaign was conducted at two urban catchments in Germany in 2018 and 2019 to investigate potential emission sources of ARs into the aquatic environment. Over several months, the occurrence and fate of all eight ARs authorized in the European Union as well as two pharmaceutical anticoagulants was monitored in a variety of aqueous, solid, and biological environmental matrices during and after widespread sewer baiting with AR-containing bait. As a result, sewer baiting in combined sewer systems, besides outdoor rodent control at the surface, was identified as a substantial contributor of these biocidal active ingredients in the aquatic environment. In conjunction with heavy or prolonged precipitation during bait application in combined sewer systems, a direct link between sewer baiting and AR residues in wastewater treatment plant influent, effluent, and the liver of freshwater fish was established.
    [Show full text]
  • Pindone for Rabbit Control: Ewicacy, Residues and Cost
    PINDONE FOR RABBIT CONTROL: EWICACY, RESIDUES AND COST PETER. C. NELSON, Pest Management Services Ltd, 28 Bancroft Terrace, Wellington, New Zealand. GRAHAM J. IDCKLING, Dept of Entomology and Animal Ecology, PO Box 84, Lincoln University, New Zealand. ABSTRACT: Toxins are a major component of rabbit control campaigns in New Zealand, with sodium monofluoroacetate (1080) being the primary toxin in use since the 1950s. However, landowners can use 1080 only under the direct supervision of a licensed operator, and rabbit populations in regularly-poisoned areas have become increasingly resistant to this form of control. A new, cost-effective toxin that does not cause persistent residues in livestock is required by landowners who wish to undertake their own rabbit control. Several recent trials have demonstrated the potential of the anticoagulant pindone (2-pivalyl-1,3-indandione) to meet these requirements. In 1992, the New Zealand Pesticides Board granted full registration to cereal pindone pellets, so that for the first time the New Zealand public has access to a rabbit bait that does not require a licence for its use. The bait is being used with apparent success in a wide range of situations, with sales of the product exceeding 100 ton in 1993. Proc. 16th Vertebr. Pest Conf. (W.S. Halverson& A.C. Crabb, Eds.) Published at Univ. of Calif., Davis. 1994. INTRODUCTION much of the responsibility and expense of rabbit control Rabbits (Oryctolagus cuniculus) were introduced to from local government organizations to landowners. The New Zealand by European settlers in the early 1800s. latter have limited access to 1080, which under current Many pastoral areas of New Zealand provided excellent legislation is available only to operators licensed by the habitat and rabbit populations soon exploded.
    [Show full text]
  • Convulsive Status Epilepticus As the Initial Presentation of Superwarfarin Poisoning: a Case Report
    7012 Case Report Convulsive status epilepticus as the initial presentation of superwarfarin poisoning: a case report Linpei Jia1#, Rufu Jia2#, Hong-Liang Zhang3,4 1Department of Nephrology, Xuanwu Hospital, Capital Medical University, Beijing, China; 2Central Hospital of Cangzhou, Cangzhou, China; 3Department of Neurology, First Hospital of Jilin University, Changchun, China; 4Department of Life Sciences, National Natural Science Foundation of China, Beijing, China #These authors contributed equally to this work. Correspondence to: Dr. Hong-Liang Zhang, MD, PhD. Department of Life Sciences, National Natural Science Foundation of China, Shuangqing Road 83#, Beijing 100085, China. Email: [email protected]. Abstract: Bromadiolone, a widely-used rodent control drug, could act as a long-acting anticoagulant. Patients of bromadiolone poisoning often present with multiorgan hemorrhage. However, neurological symptoms of bromadiolone poisoning are seldom reported. We report a rare case with convulsive status epilepticus as the initial presentation of bromadiolone poisoning. A previously healthy 18-year-old man presented with persistent unconsciousness and repeated convulsive seizures. Magnetic resonance imaging revealed lesions in the corpus callosum. Laboratory test revealed the microscopic hematuria, prolonged prothrombin time, prolonged activated partial thromboplastin time and the presence of bromadiolone. The patient was diagnosed as the bromadiolone poisoning and treated with hemofiltration, vitamin K and prothrombin complex. Consciousness of the patient was regained and all neurological symptoms diminished after 7 days. Coagulopathy was totally corrected after 3 weeks, and a 2-month regimen of vitamin K supplementation was prescribed after discharge. Our case suggests that bromadiolone poisoning may involve the central nervous system. The atypical and initial symptoms of neurological disorders might lead to misdiagnosis of bromadiolone poisoning.
    [Show full text]
  • Chemical Hygiene Plan
    DIVISION OF NATURAL SCIENCES CHEMICAL HYGIENE PLAN Pacific Lutheran University Chemical Hygiene Plan CHEMICAL HYGIENE PLAN Emergency reference numbers: Police, Fire, or Ambulance ..................................... 9-911 Campus Safety ....................................................... x7911 Acknowledgement Pacific Lutheran University would like to acknowledge the University of Illinois at Urbana-Champaign, Davidson College, and Saint Olaf College, from whom we have adopted portions of this Chemical Hygiene Plan. Revision Date: December 2017 2 Pacific Lutheran University Chemical Hygiene Plan Table of Contents Chapter 1: Introduction .................................................................................................................................. 4 1.1 Chemical Hygiene Plan Roles and Responsibilities ....................................................................... 4 1.2 OSHA Laboratory Standard: Purpose/Scope/Application .............................................................. 8 1.3 Additional Regulatory Information .................................................................................................. 9 Chapter 2: Standard Operating Procedures ............................................................................................... 11 2.1 General Procedures ..................................................................................................................... 11 2.2 Pollution Prevention and Waste Minimization .............................................................................
    [Show full text]